• Je něco špatně v tomto záznamu ?

Variations in mismatch repair genes and colorectal cancer risk and clinical outcome

V. Vymetalkova, B. Pardini, F. Rosa, C. Di Gaetano, J. Novotny, M. Levy, T. Buchler, J. Slyskova, L. Vodickova, A. Naccarati, P. Vodicka,

. 2014 ; 29 (4) : 259-265.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014369

Grantová podpora
NT12025 MZ0 CEP - Centrální evidence projektů

DNA mismatch repair (MMR) deficiency is one of the best understood forms of genetic instability in colorectal cancer (CRC). CRC is routinely cured by 5-fluorouracil (5-FU)-based chemotherapy, with a prognostic effect and resistance to such therapy conferred by MMR status. In this study, we aimed to analyse the effect of genetic variants in classical coding regions or in less-explored predicted microRNA (miRNA)-binding sites in the 3' untranslated region (3'UTR) of MMR genes on the risk of CRC, prognosis and the efficacy of 5-FU therapy. Four single nucleotide polymorphisms (SNPs) in MMR genes were initially tested for susceptibility to CRC in a case-control study (1095 cases and 1469 healthy controls). Subsequently, the same SNPs were analysed for their role in survival on a subset of patients with complete follow-up. Two SNPs in MLH3 and MSH6 were associated with clinical outcome. Among cases with colon and sigmoideum cancer, carriers of the CC genotype of rs108621 in the 3'UTR of MLH3 showed a significantly increased survival compared to those with the CT + TT genotype (log-rank test, P = 0.05). Moreover, this polymorphism was also associated with an increased risk of relapse or metastasis in patients with heterozygous genotype (log-rank test, P = 0.03). Patients carrying the CC genotype for MSH6 rs1800935 (D180D) and not undergoing 5-FU-based chemotherapy showed a decreased number of recurrences (log-rank test, P = 0.03). No association with CRC risk was observed. We provide the first evidence that variations in potential miRNA target-binding sites in the 3'UTR of MMR genes may contribute to modulate CRC prognosis and predictivity of therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014369
003      
CZ-PrNML
005      
20200428161252.0
007      
ta
008      
150420s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/mutage/geu014 $2 doi
035    __
$a (PubMed)24755277
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vymetálková, Veronika $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Katerinska 32, 12800 Prague, Czech Republic, vpolakova@biomed.cas.cz. $7 xx0102721
245    10
$a Variations in mismatch repair genes and colorectal cancer risk and clinical outcome / $c V. Vymetalkova, B. Pardini, F. Rosa, C. Di Gaetano, J. Novotny, M. Levy, T. Buchler, J. Slyskova, L. Vodickova, A. Naccarati, P. Vodicka,
520    9_
$a DNA mismatch repair (MMR) deficiency is one of the best understood forms of genetic instability in colorectal cancer (CRC). CRC is routinely cured by 5-fluorouracil (5-FU)-based chemotherapy, with a prognostic effect and resistance to such therapy conferred by MMR status. In this study, we aimed to analyse the effect of genetic variants in classical coding regions or in less-explored predicted microRNA (miRNA)-binding sites in the 3' untranslated region (3'UTR) of MMR genes on the risk of CRC, prognosis and the efficacy of 5-FU therapy. Four single nucleotide polymorphisms (SNPs) in MMR genes were initially tested for susceptibility to CRC in a case-control study (1095 cases and 1469 healthy controls). Subsequently, the same SNPs were analysed for their role in survival on a subset of patients with complete follow-up. Two SNPs in MLH3 and MSH6 were associated with clinical outcome. Among cases with colon and sigmoideum cancer, carriers of the CC genotype of rs108621 in the 3'UTR of MLH3 showed a significantly increased survival compared to those with the CT + TT genotype (log-rank test, P = 0.05). Moreover, this polymorphism was also associated with an increased risk of relapse or metastasis in patients with heterozygous genotype (log-rank test, P = 0.03). Patients carrying the CC genotype for MSH6 rs1800935 (D180D) and not undergoing 5-FU-based chemotherapy showed a decreased number of recurrences (log-rank test, P = 0.03). No association with CRC risk was observed. We provide the first evidence that variations in potential miRNA target-binding sites in the 3'UTR of MMR genes may contribute to modulate CRC prognosis and predictivity of therapy.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a kolorektální nádory $x genetika $7 D015179
650    _2
$a oprava chybného párování bází DNA $x genetika $7 D053843
650    _2
$a enzymy opravy DNA $x genetika $7 D045643
650    _2
$a ženské pohlaví $7 D005260
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jednonukleotidový polymorfismus $x genetika $7 D020641
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pardini, Barbara $u Human Genetics Foundation, Via Nizza 52, 10126 Turin, Italy. $7 _AN058834
700    1_
$a Rosa, Fabio $u Human Genetics Foundation, Via Nizza 52, 10126 Turin, Italy.
700    1_
$a Di Gaetano, Cornelia $u Human Genetics Foundation, Via Nizza 52, 10126 Turin, Italy, Department of Medical Sciences, University of Turin, Via Verdi 8, 10124 Turin, Italy.
700    1_
$a Novotný, Jan, $u Department of Oncology, First Faculty of Medicine, Charles University, Katerinska 32, 12800 Prague, Czech Republic. $d 1971- $7 jo2003184375
700    1_
$a Levý, Miroslav $u Department of Surgery, First Faculty of Medicine, Charles University, Katerinska 32, 12800 Prague, Czech Republic and. $7 xx0198664
700    1_
$a Büchler, Tomáš, $d 1974- $u Department of Surgery, First Faculty of Medicine, Charles University, Katerinska 32, 12800 Prague, Czech Republic and Thomayer University Hospital, Videnska 800, 14059 Prague, Czech Republic. $7 xx0096851
700    1_
$a Slysková, Jana $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Katerinska 32, 12800 Prague, Czech Republic. $7 _AN077444
700    1_
$a Vodičková, Ludmila $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Katerinska 32, 12800 Prague, Czech Republic. $7 xx0128157
700    1_
$a Naccarati, Alessio $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic, Human Genetics Foundation, Via Nizza 52, 10126 Turin, Italy.
700    1_
$a Vodička, Pavel $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine, Videnska 1083, 14200 Prague, Czech Republic, Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Katerinska 32, 12800 Prague, Czech Republic. $7 xx0060269
773    0_
$w MED00003429 $t Mutagenesis $x 1464-3804 $g Roč. 29, č. 4 (2014), s. 259-265
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24755277 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20200428161244 $b ABA008
999    __
$a ok $b bmc $g 1071950 $s 897247
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 29 $c 4 $d 259-265 $i 1464-3804 $m Mutagenesis $n Mutagenesis $x MED00003429
GRA    __
$a NT12025 $p MZ0
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Možnosti archivace